Independent , Honest and Dignified Journalism

Centre Targets January 2027 Rollout of Rs 10,000-Crore Biopharma SHAKTI Scheme

The five year initiative aims to strengthen India's domestic biologics and biosimilars industry, support research and clinical development, and build an integrated manufacturing ecosystem for advanced medicines.

NEW DELHI, Nov 20: The Centre is targeting January 2027 for the implementation of its proposed Rs 10,000-crore Biopharma SHAKTI programme, an initiative designed to strengthen India’s domestic biopharmaceutical industry and establish the country as a major global manufacturing hub for biologics and biosimilars.

The Department of Pharmaceuticals is currently finalising the policy framework, which is expected to be submitted to the Union Cabinet for approval before implementation.

Satyaprakash T L, Joint Secretary in the Department of Pharmaceuticals, said the government was preparing to place the final policy before the Cabinet and intended to begin implementing the programme by January next year.

He explained that the initiative would support contract research, development and manufacturing organisations (CRDMOs), while strengthening the clinical research ecosystem required for the development and testing of advanced biopharmaceutical products.

The proposed programme carries a financial allocation of Rs 10,000 crore over five years, covering the financial period from 2026-27 to 2030-31.

Announced in the Union Budget 2026-27, Biopharma SHAKTI stands for Strategy for Healthcare Advancement through Knowledge, Technology and Innovation. It aims to create an integrated ecosystem covering research, development, clinical testing and domestic manufacturing of biologics and biosimilars.

The initiative represents an important step in India’s efforts to expand its pharmaceutical capabilities beyond conventional chemical-based medicines and strengthen its position in advanced biotechnology.

Focus on advanced medicines

Biopharmaceutical products are developed using biological sources, including living cells and microorganisms, and are used in treating several complex diseases. Biologics and biosimilars have become important components of modern medical treatment, particularly in areas where conventional medicines may have limitations.

Biologics include products such as therapeutic proteins, antibodies and other medicines developed through biological processes. Biosimilars are highly similar versions of already approved biological medicines, developed to provide additional treatment options after the original products lose market exclusivity.

Their development and manufacturing require specialised facilities, advanced scientific knowledge, strict quality controls and sophisticated production technologies.

Through Biopharma SHAKTI, the government intends to develop the infrastructure and institutional capabilities needed to support these activities within the country.

The programme is expected to strengthen the entire value chain, beginning with scientific research and continuing through product development, clinical evaluation and commercial manufacturing.

An important component will be support for CRDMOs, which provide specialised services to pharmaceutical and biotechnology companies. These organisations undertake research, develop manufacturing processes and help produce medicines for clinical trials and commercial requirements.

Strengthening this segment could provide domestic biotechnology companies with improved access to specialised infrastructure and technical expertise.

The government also intends to improve the country’s clinical research ecosystem. Clinical development is an essential stage in bringing new medicines to patients because potential treatments must undergo systematic evaluation to establish their safety, effectiveness and appropriate use.

A stronger research and testing network could help domestic companies undertake more development activities within India and reduce dependence on external facilities.

Addressing the growing disease burden

The proposed scheme is expected to prioritise projects involving non-communicable diseases, including diabetes, cancer and autoimmune disorders.

These conditions represent significant healthcare challenges because they frequently require long-term treatment, specialised medical supervision and access to advanced therapies.

Cancer treatment, for example, increasingly involves targeted medicines and biological therapies designed to act on specific mechanisms associated with the disease. Similarly, advances in biotechnology have created new possibilities for managing certain autoimmune conditions through specialised treatments.

Diabetes research has also expanded beyond conventional glucose management, with scientific attention increasingly directed towards metabolic processes, complications and innovative therapeutic approaches.

The proposed programme could help create a stronger domestic ecosystem for developing and manufacturing advanced medicines in these areas.

However, the precise allocation of funds across individual disease categories and projects has not yet been specified. The initial funding priorities will become clearer as the government finalises the policy framework and implementation guidelines.

The initiative is expected to connect India’s pharmaceutical manufacturing strengths with its expanding biotechnology research capabilities.

Reducing dependence on imported technologies

India has established itself as an important supplier of generic medicines and vaccines to international markets. However, the development and manufacturing of complex biological products require different infrastructure, specialised production processes and substantial research investments.

Expanding domestic capabilities in this segment could help the pharmaceutical industry diversify its manufacturing base and participate more actively in the global biopharmaceutical market.

The proposed investment is intended to encourage companies to establish advanced manufacturing facilities, improve research infrastructure and develop specialised technical capabilities.

It could also create opportunities for domestic biotechnology startups and research organisations working on innovative medical technologies.

For smaller companies, access to specialised manufacturing and clinical development facilities can be an important factor in moving scientific discoveries towards commercial applications.

CRDMOs can provide these services without requiring every biotechnology company to establish its own complete manufacturing infrastructure. This arrangement may improve efficiency and allow researchers to concentrate on developing new products.

The programme’s emphasis on research and manufacturing together is significant because scientific discoveries alone are not sufficient to ensure that new medicines become widely available.

A successful biotechnology ecosystem requires coordination between laboratories, manufacturers, clinical research organisations, regulators and healthcare providers.

Strengthening India’s biotechnology ecosystem

The development of a domestic biopharmaceutical industry also depends on the availability of skilled professionals, modern laboratories and reliable supply chains.

Biological medicines require specialised production environments and carefully controlled processes to maintain product quality. Manufacturing facilities must meet stringent standards, while research teams need expertise in biotechnology, molecular biology, pharmaceutical sciences and clinical development.

The proposed initiative could encourage greater investment in these areas and strengthen cooperation between academic institutions, research centres and private-sector manufacturers.

Partnerships between public and private organisations may also help convert research findings into products suitable for further development.

India’s large pharmaceutical manufacturing base provides an existing foundation for this expansion. However, moving towards more complex biological products will require sustained investment in technology, infrastructure and specialised skills.

The five-year duration of the programme is intended to provide a longer-term framework for building these capabilities rather than limiting support to short-term manufacturing requirements.

The government has not yet specified the year-wise distribution of the Rs 10,000-crore allocation. Further details regarding eligibility, funding arrangements and the selection of projects are expected to emerge after the policy receives the necessary approvals.

Potential implications for patients

A stronger domestic biopharmaceutical industry could have important implications for patients requiring advanced and long-term medical treatment.

Greater domestic production capacity may improve the availability of certain medicines and strengthen competition in the market. Depending on manufacturing costs, regulatory approvals and market conditions, this could also create opportunities for more affordable treatment options.

Patients suffering from cancer, diabetes and autoimmune disorders may particularly benefit from a wider range of treatment choices as research and manufacturing capabilities expand.

However, the development of new medicines involves lengthy scientific and regulatory processes. Any product developed under the programme would still need to satisfy applicable safety, quality and efficacy requirements before being made available for clinical use.

The initiative should therefore be viewed as a long-term investment in India’s healthcare and pharmaceutical infrastructure rather than an immediate expansion of treatment availability.

A push towards global competitiveness

The proposed Biopharma SHAKTI programme also reflects the government’s ambition to increase India’s participation in the global biotechnology industry.

International demand for biologics and biosimilars has created opportunities for countries capable of offering high-quality research, development and manufacturing services.

India’s established pharmaceutical industry, scientific workforce and expanding biotechnology sector could provide a foundation for attracting additional investment in this field.

By supporting CRDMOs and strengthening clinical research facilities, the programme seeks to develop an environment in which companies can undertake more activities within the country.

The initiative may also encourage greater collaboration between Indian manufacturers and international pharmaceutical companies seeking research and production partnerships.

For the domestic industry, the challenge will be to combine technological advancement with internationally competitive manufacturing standards.

The government will need to ensure that funding is directed towards projects capable of developing sustainable capabilities and generating measurable improvements in research and production.

The January 2027 implementation target will mark the beginning of the next phase of the programme, subject to the completion of the approval process.

Once the policy framework is finalised, the focus will shift towards identifying eligible organisations, establishing implementation arrangements and supporting projects across the biopharmaceutical value chain.

With an investment commitment of Rs 10,000 crore over five years, Biopharma SHAKTI is expected to play an important role in India’s efforts to move towards higher-value pharmaceutical manufacturing.

The broader objective is to build a domestic ecosystem capable of supporting innovation, advanced drug development and large-scale production while improving the country’s competitiveness in international healthcare markets.

WhatsApp Channel